Back to News
Market Impact: 0.35
AbbVie's EPKINLY Receives Health Canada Approval For Follicular Lymphoma
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Health Canada issued a Notice of Compliance for AbbVie's EPKINLY (epcoritamab) combined with lenalidomide and rituximab for adults with relapsed or refractory Grade 1, 2, or 3a follicular lymphoma after at least one prior treatment line. The approval expands EPKINLY's addressable use in Canada and is a positive regulatory milestone for AbbVie's oncology portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
ABBV0.72
More News
- SEBI Allows Portfolio Managers to Invest Overseas, Short Equity Options
- Trump, Xi Address AI, Taiwan During State Visit
- U.S. government seeks to join Elon Musk in challenge against EU's fine on X
- Tesla poised to scale production of heavy-duty Semi trucks with opening of Nevada factory
- Here’s the Tesla Semi… again
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly